Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Consider this SGLT2 inhibitor for patients with HF with preserved ejection fraction: The addition of empagliflozin to usual therapy reduced hospitalization risk, regardless of patients' diabetes status.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Subject Terms:
- Abstract:
The article presents the study in which the empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction was conducted to evaluate the effects of sodium-glucose cotransporter 2 inhibition with empagliflozin in patients with heart failure with preserved ejection fraction. The treatment significantly reduced the risk of hospitalization for heart failure, regardless of whether patients had diabetes.
No Comments.